

## FUSIONPlex Core Solid Tumor

### Description

The FUSIONPlex Core Solid Tumor panel is a balanced pool of gene-specific primer (GSP) oligonucleotides that is optimized for use with FUSIONPlex reagents and molecular barcode (MBC) adapters to produce targeted NGS libraries. This product insert should be used in conjunction with FUSIONPlex protocol for Illumina® (RA-DOC-047) or FUSIONPlex protocol for Ion Torrent<sup>™</sup> (RA-DOC-048).

FUSIONPlex Core Solid Tumor panel contains **797** GSPs targeting **57** genes.

Description	Part number	Storage
FUSIONPlex Core Solid Tumor GSP1, 8 reactions	SA22408081	
FUSIONPlex Core Solid Tumor GSP2, 8 reactions	SA22408082	-20°C ± 10°C
10X VCP Primer Mix	SA0126	

### Recommended PCR cycling

	Step	Temperature (°C)	Time	Cycles
First PCR reaction	1	95	3 min	1
	2	95	30 sec	
	3	60	10 sec	15
	4	63	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

## Recommended PCR cycling (cont.)

	Step	Temperature (°C)	Time	Cycles
Second PCR reaction	1	95	3 min	1
	2	95	30 sec	
	3	60	10 sec	20†
	4	65	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

†The number of PCR2 cycles may be decreased if you regularly experience library yields greater than 200 nM.

## Recommended reads and multiplexing

FUSIONPlex Core Solid Tumor libraries should be sequenced to a minimum of **3M**. Starting read depth recommendations for standard profiling may be adjusted based on user needs.

## Archer™ Analysis settings

Sequencing data should be processed using Archer Analysis (v7.0, or greater). The FUSIONPlex Core Solid Tumor panel requires selection of the of the **Fusion** and (optional) **SNV/Indel** pipeline(s), found under the **RNA** Input Type (see the Archer Analysis User Guide for more details on setting up your analysis).

Processing of FUSIONPlex Core Solid Tumor panel libraries requires a one-time upload of a target region file (a text file, in GTF format, which directs the software on how to analyze data from the panel). For SNV/Indel detection it is recommended to perform the analysis using a targeted mutations file. Files can be obtained by contacting [archer-tech@idtdna.com](mailto:archer-tech@idtdna.com)

## Assay targets

Gene	Accession	Exon	Variant type	Description**
AKT1	NM_005163	3	Mutation	Hotspot coverage including p.E17
AKT1	NM_005163	2, 3, 4, 5, mid-exon5	Fusion, Expression	5'
ALK	NM_004304	1, 2	Internal deletion (ALKΔ2-17, ALKΔ2-3)	3'

Gene	Accession	Exon	Variant type	Description**
<i>ALK</i>	NM_004304	2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 19, intron19, 20, mid-exon20, 21, 22, 23, 26	Fusion, ALK AT1 <sup>y</sup> , Internal deletion (ALKΔ2-17, ALKΔ2-3), Expression	5'
<i>ALK</i>	NM_004304	21, 22, 23, 24, 25	Mutation	Full exon coverage including p.P1153-p.C1156, p.F1174, p.L1196-p.S1206, p.G1269
<i>ALK</i>	NM_004304	9, 12, 16, 20	Mutation	Hotspot coverage including p.V597, p.H694, p.G881, p.K1062
<i>AXL</i>	NM_021913	18, 19, mid-exon20, 20	Fusion	3'
<i>AXL</i>	NM_021913	11	Fusion	5'
<i>BRAF</i>	NM_004333	1, 2, 3, 7, 8, 10, 13, 14, 18	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8	3'
<i>BRAF</i>	NM_004333	2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 15, 16	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8, Expression	5'
<i>BRAF</i>	NM_004333	11, 15	Mutation	Full exon coverage including p.V600
<i>BRD3</i>	NM_007371	9, 10, 11, 12	Fusion	3'
<i>BRD4</i>	NM_058243	2*	Fusion	5'
<i>BRD4</i>	NM_058243	10, 11, 12, 13, 14	Fusion	3'
<i>CTNNB1</i>	NM_001904	3	Mutation	Full exon coverage
<i>CTNNB1</i>	NM_001904	8	Mutation	Hotspot coverage including p.W383-p.N387
<i>CYSLTR2</i>	NM_020377	5	Mutation	Hotspot p.L129
<i>DDR2</i>	NM_006182	17	Mutation	Full exon coverage
<i>DNAJB1</i>	NM_006145	1, 2	Fusion	3'
<i>EGFR</i>	NM_005228	1, 24, 25, mid-exon25, 26	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication	3'

Gene	Accession	Exon	Variant type	Description**
<i>EGFR</i>	NM_005228	7, 8, 9, 14, 15, 16, 17, 18, 19, 20	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication, Expression	5'
<i>EGFR</i>	NM_005228	18, 19, 20, 21	Mutation	Full exon coverage including p.E709-p.G719, p.E746-p.L760, p.V774-p.G796, p.L858-p.L861
<i>ERBB2</i>	NM_004448	15, 23, 24, 25, mid-exon26, 26	Fusion, Exon 16 skipping ( $\Delta$ 16HER)	3'
<i>ERBB2</i>	NM_004448	4, 5, 13, 15, 17	Fusion, Exon 16 skipping ( $\Delta$ 16HER), Expression	5'
<i>ERBB2</i>	NM_004448	17, 18, 19, 20, 21	Mutation	Full exon coverage including p.Y772-p.P780, p.C805
<i>ERBB2</i>	NM_004448	6, 7, 8, 12, 16	Mutation	Hotspot coverage including p.G222, p.E265, p.D277, p.G309, p.S310, p.C311, p.E321, p.C334, p.A440, p.R487, p.A644, p.E645, p.S649
<i>ERBB4</i>	NM_005235	2, 3, 4, 14, 15, 16, 17, 18, 23	Fusion	5'
<i>ERBB4</i>	NM_005235	7, 8, 12, 14, 15, 18, 20, 21, 23, 25, 27, 28	Mutation	Hotspot coverage including p.Y285, p.S303, p.R306, p.E317, p.E452, p.E542, p.R544, p.E563, p.D595, p.Q707, p.S774, p.L798, p.E836, p.D843, p.E872, p.D931, p.K935, p.K1002, p.F1102, p.K1223, p.R1275, p.S1289
<i>ERG</i>	NM_004449	2*, 3*, 4, 5, 6, 7, 8, 9, 10, 11	Fusion	5'
<i>ESR1</i>	NM_000125	1, 2, 3, 4, 5, 6, 7	Fusion	3'
<i>ESR1</i>	NM_000125	5, 6, 7, 8	Fusion	5'
<i>ESR1</i>	NM_000125	5, 6, 7, 8	Mutation	Hotspot coverage including p.E380, p.V422, p.S463, p.L469, p.L536, p.Y537, p.D538

Gene	Accession	Exon	Variant type	Description**
<i>FGFR1</i>	NM_015850	12, 17	Fusion, Kinase Domain Duplication	3'
<i>FGFR1</i>	NM_015850	2*, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17	Fusion, Kinase Domain Duplication, Expression	5'
<i>FGFR1</i>	NM_023110	4, 13, 14	Mutation	Hotspot coverage including p.T141, p.V561, p.N546, p.K656
<i>FGFR2</i>	NM_000141	16, 17, 18	Fusion	3'
<i>FGFR2</i>	NM_000141	2*, 3, 5, 6, 7, 8, 9, 10	Fusion	5'
<i>FGFR2</i>	NM_000141	7, 8, 9, 12, 13, 14	Mutation	Hotspot coverage including p.S252, p.P253, p.G305, p.A314, p.Y375, p.C382, p.M391, p.V395, p.M537, p.I547, p.N549, p.V564, p.E565, p.K641, p.A648, p.K659
<i>FGFR3</i>	NM_000142	16, 17, intron17, mid-exon18	Fusion	3'
<i>FGFR3</i>	NM_000142	3, 5, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
<i>FGFR3</i>	NM_000142	7, 9, 13, 14, 16	Mutation	Hotspot coverage including p.R248, p.S249, p.G370, p.S371, p.Y373, p.G380, p.R399, p.V555, p.D641, p.K650, p.G697, p.K715
<i>GNA11</i>	NM_002067	4, 5	Mutation	Hotspot coverage including p.R183, p.Q209
<i>GNAQ</i>	NM_002072	4, 5	Mutation	Hotspot coverage including p.R183, p.Q209
<i>GNAS</i>	NM_000516	8, 9	Mutation	Hotspot coverage including p.R201, p.Q227
<i>H3F3A</i>	NM_002107	2	Mutation	Hotspot coverage including p.K28
<i>HIST1H3B</i>	NM_003537	1	Mutation	Full exon coverage including p.K28
<i>HRAS</i>	NM_005343	2, 3, 4	Mutation	Full exon coverage including p.G12, p.G13, p.Q61, p.K117, p.A146

Gene	Accession	Exon	Variant type	Description**
<i>IDH1</i>	NM_005896	4, 5	Mutation	Hotspot coverage including p.G97, p.R100, p.R132, p.Y139
<i>IDH2</i>	NM_002168	4	Mutation	Hotspot coverage including p.R140, p.R172
<i>KEAP1</i>	NM_203500	2, 3, 4, 5, 6	Mutation	Full exon coverage
<i>KIT</i>	NM_000222	1	Fusion	3'
<i>KIT</i>	NM_000222	8	Fusion	5'
<i>KIT</i>	NM_000222	9, 10, 11, 13, 14, 17, 18	Mutation	Full exon coverage
<i>KRAS</i>	NM_004985	2, 3, 4	Mutation	Full exon coverage including p.G12, p.G13, p.Q61, p.K117, p.A146
<i>KRAS</i>	NM_004985	5	Mutation	Hotspot coverage including p.D153, p.F156
<i>LTK</i>	NM_002344	2, 3, 4, 5, 8, 9, 10, 11, 12, 13	Fusion	5'
<i>LTK</i>	NM_001135685	10	Fusion	5'
<i>MAP2K1</i>	NM_002755	2	Fusion	5'
<i>MAP2K1</i>	NM_002755	2, 3, 5, 6	Mutation	Full exon coverage including p.F53, p.D67
<i>MAP3K3</i>	NM_002401	8	Fusion	5'
<i>MAP3K8</i>	NM_005204	8	Fusion	3'
<i>MET</i>	NM_000245	2, 13	Fusion, Exon 14 Skipping (METΔex14)	3'
<i>MET</i>	NM_000245	2, 4, 5, 6, 13, 14, 15, 16, 17, 21	Fusion, Exon 14 Skipping (METΔex14)	5'
<i>MET</i>	NM_000245	14, 15, 16, 17, 18, 19, 20	Mutation	Full exon coverage
<i>MYB</i>	NM_001130173	7, 8, 9, 11, 12, 13, 14, 15, 16	Fusion	3'
<i>MYBL1</i>	NM_001080416	8, 9, mid-exon10, 10, 11, 12, 13, 14, 15	Fusion	3'
<i>NRAS</i>	NM_002524	2, 3, 4	Mutation	Full exon coverage including p.G12, p.G13, p.Q61, p.K117, p.A146
<i>NRG1</i>	NM_001159996	1*, 3, 4, 5	Fusion	5'

Gene	Accession	Exon	Variant type	Description**
<i>NRG1</i>	NM_004495	1, 2, 3, 4, 5, 6	Fusion	5'
<i>NRG1</i>	NM_013958	1*	Fusion	5'
<i>NRG1</i>	NM_013959	1*, 3	Fusion	5'
<i>NRG1</i>	NM_013962	1	Fusion	3'
<i>NRG1</i>	NM_013962	1*	Fusion	5'
<i>NTRK1</i>	NM_001007792	1, 2	Fusion	5'
<i>NTRK1</i>	NM_002529	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
<i>NTRK1</i>	NM_002529	13, 14, 15, 16, 17	Mutation	Full Kinase Domain coverage for resistance mutations including p.G595
<i>NTRK2</i>	NM_006180	11, 14	Fusion	3'
<i>NTRK2</i>	NM_006180	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'
<i>NTRK2</i>	NM_006180	16, 17, 18, 19, 20, 21	Mutation	Full Kinase Domain coverage for resistance mutations
<i>NTRK3</i>	NM_001007156	15	Fusion	5'
<i>NTRK3</i>	NM_002530	13, 14, 15, 17	Fusion	3'
<i>NTRK3</i>	NM_002530	3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16	Fusion	5'
<i>NTRK3</i>	NM_002530	15, 16, 17, 18, 19	Mutation	Full Kinase Domain coverage for resistance mutation detection including p.F617,p.G623,p.G696
<i>NUTM1</i>	NM_175741	2*, 3, mid-exon3, 4, 5, mid-exon6, 6	Fusion	5'
<i>PAX8</i>	NM_003466	1*, 2, 6, 7, 8, 9, 10	Fusion	3'
<i>PAX8</i>	NM_003466	3	Fusion	5'
<i>PDGFRA</i>	NM_006206	6, 7	Fusion,PDGFRAΔ8,9	3'
<i>PDGFRA</i>	NM_006206	10, 11, 12, mid-exon12, 13, 14, 15	Fusion,PDGFRAΔ8,9	5'
<i>PDGFRA</i>	NM_006206	12, 14, 18	Mutation	Full exon coverage including p.D842
<i>PDGFRA</i>	NM_006206	6, 15	Mutation	Hotspot coverage including p.Y288, p.T674

Gene	Accession	Exon	Variant type	Description**
<i>PIK3CA</i>	NM_006218	2, 15	Fusion	5'
<i>PIK3CA</i>	NM_006218	2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 19, 20, 21	Mutation	Hotspot coverage including p.E81K-p.G118,p.L339-p.D350,p.G364,p.E418-p.C420,p.E453-p.K468,p.P539-p.Q546,p.E726,p.Y1021-p.T1052
<i>POLD1</i>	NM_002691	8, 9, 10, 11, 12	Mutation	Full exon coverage
<i>POLE</i>	NM_006231	9, 10, 11, 12, 13, 14	Mutation	Full exon coverage
<i>PPARG</i>	NM_015869	1, 2, 3	Fusion	5'
<i>PRKCA</i>	NM_002737	4, 5, 6, 9, 15	Fusion	5'
<i>PRKCB</i>	NM_002738	1, 3, 7, 8, 9	Fusion	5'
<i>RAF1</i>	NM_002880	4, 5, 6, 7, 8, 9	Fusion	3'
<i>RAF1</i>	NM_002880	2*, 4, 5, 6, 7, 8, 9, 10, 11, 12	Fusion	5'
<i>RET</i>	NM_020630	2, 4, 6, 8, 9, 10, 11, mid-exon11, 12, 13, 14	Fusion	5'
<i>RET</i>	NM_020630	8, 10, 11, 13, 14, 15, 16	Mutation	Hotspot coverage including p.A883, p.M918
<i>ROS1</i>	NM_002944	2, 4, 7, 31, 32, 33, 34, 35, 36, 37	Fusion	5'
<i>ROS1</i>	NM_002944	38, 39, 40	Mutation	Hotspot coverage including p.G2032, p.C2060, p.V2098, p.G2101
<i>STK11</i>	NM_000455	1, 2, 3, 4, 5, 6, 7, 8, 9	Mutation	Full exon coverage
<i>TMPRSS2</i>	NM_001135099	1	Fusion	3'
<i>TMPRSS2</i>	NM_005656	1*, 2, 3, 4, 5, 6	Fusion	3'
<i>TP53</i>	NM_000546	2, 3, 4, 5, 6, 7, 8, 9, 10, 11	Mutation	Full exon coverage
<i>TRIM11</i>	NM_145214	2, 3	Fusion	5'

\*Indicates exons that are entirely untranslated region (UTR), or for which the UTR is targeted.

\*\*Contact [archer-tech@idtdna.com](mailto:archer-tech@idtdna.com) for the panel target file to view complete list of targeted regions. *De Novo* RNA SNV/Indel detection is not supported on the Ion Torrent sequencing platform.

†ALK-AT1 currently requires review outside of Archer Analysis.



## Limitations of use

**For research use only. Not for use in diagnostic procedures.** Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Safety data sheets pertaining to this product are available upon request.

This product or service is licensed under one or more of the following U.S. Patents: 8,835,358; 9,290,808; 9,290,809; 9,315,857; 9,708,659; and 9,816,137 owned by BD and is licensed solely for the use described in the associated product literature. No other rights, implied or otherwise, are granted to purchaser hereunder. Purchaser agrees, by way of example and not limitation, not to use this product to trace back the origin of a nucleic acid to an individual cell as a discrete entity (e.g., single cell analysis).

© 2023 Integrated DNA Technologies, Inc. All rights reserved. FUSIONPlex, VARIANTPlex, LIQUIDPlex, IMMUNOVERSE, Archer Analysis, and Archer Assay Marketplace are trademarks of Integrated DNA Technologies, Inc. All other marks are the property of their respective owners. For specific trademark and licensing information, see [www.idtdna.com/trademarks](http://www.idtdna.com/trademarks).

## Revision History

Document Number	Date	Description of change
RA-DOC-060/REV01	June 2023	Initial release
RA-DOC-060/REV02	November 2023	Updated First and Second PCR cycling conditions to include separate anneal and extended steps.  Listed additional exons targeted for fusion in NTRK2 and ROS1.  Updated branding.